Avience Biomedicals IPO GMP on Day 1 of Subscription, 18 June 2026: Grey Market Premium at ₹70, Expected Listing at ₹278
- June 18, 2026
- Posted by: Ankit Jaiswal
- Category: IPO
Avience Biomedicals IPO GMP Day 1, 18 June 2026: GMP ₹70. Price band ₹196 to ₹208. Lot 1200 shares. Min investment ₹2,49,600. Listing June 25, 2026 on NSE SME.
The avience biomedicals ipo gmp on Day 1 of subscription, 18 June 2026, stands at ₹70. The Avience Biomedicals IPO opened for subscription on June 18, 2026 and closes on June 22, 2026, a book built issue raising ₹30.24 Cr at a price band of ₹196 to ₹208 per share on the NSE SME platform. The implied expected listing price based on the current GMP is ₹278, approximately 33.7% above the issue price.
Kunal Singla, Associate Director at Univest explains what the Avience Biomedicals IPO GMP signals, what the company does and the key factors investors should weigh before the close of subscription on June 22, 2026.
Click Here – Get Free Investment Predictions
Avience Biomedicals IPO GMP: Complete Snapshot
| Detail | Information |
|---|---|
| IPO open date | June 18, 2026 |
| IPO close date | June 22, 2026 |
| Allotment date | June 23, 2026 |
| Listing date | June 25, 2026 |
| Issue size | ₹30.24 Cr |
| Price band | ₹196 to ₹208 |
| Lot size | 600 shares |
| Min retail application | 1200 shares (₹2,49,600) |
| Issue type | Book Built |
| Exchange | NSE SME |
| Investor quota | 35% retail, 50% QIB, 15% NII |
| Registrar | Skyline Financial Services Pvt. Ltd. |
| Lead manager | FinTellectual Corporate Advisors Pvt. Ltd. |
| Avience Biomedicals IPO GMP (Day 1) | ₹70 |
| Expected listing price | ₹278 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has now shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks on Univest
The table above captures the full snapshot for the Avience Biomedicals IPO GMP as of Day 1 of subscription. Every figure should be verified from the official BSE, NSE and registrar websites before applying.
Avience Biomedicals IPO GMP Day 1: What the Grey Market is Saying
The Avience Biomedicals IPO GMP stands at ₹70 on Day 1 of subscription. This implies an expected listing price of ₹278, approximately 33.7% above the issue price of ₹196 to ₹208. The positive grey market reading suggests that unofficial market participants are expecting meaningful listing gains, though this can shift rapidly as subscription data comes in over the next sessions.
It is important to treat IPO GMP as an informal sentiment indicator only. The grey market is unregulated, and premiums can change sharply between Day 1 and the listing date based on overall subscription, market conditions and sector sentiment.
About Avience Biomedicals: What Does the Company Do?
Avience Biomedicals Limited, incorporated in June 2024 and headquartered in Noida, Uttar Pradesh, is an ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions focused on biotechnology, genomics and in-vitro diagnostics. Its product range includes rapid test kits, biochemistry analyzers, molecular diagnostics, hematology analyzers, medical devices and serology products. The company serves pathology labs, hospitals, microbiology labs and research centers in India and overseas. Revenue grew from Rs 24.37 crore in FY24 to Rs 45.97 crore in FY25, while profit after tax rose from Rs 2.14 crore to Rs 7.23 crore in the same period.
Avience Biomedicals IPO: Key Financial Metrics
| Metric | Value |
|---|---|
| Revenue FY25 / FY24 | ₹45.97 Cr / ₹24.37 Cr |
| PAT FY25 / FY24 | ₹7.23 Cr / ₹2.14 Cr |
Investors should verify these figures from the official Red Herring Prospectus available on the BSE and NSE websites before using them in any investment decision related to the Avience Biomedicals IPO GMP.
How to Apply for the Avience Biomedicals IPO
The Avience Biomedicals IPO can be applied through the ASBA route via your bank’s net banking or through UPI via your stockbroker’s platform. The subscription window is open until June 22, 2026. Retail investors must apply for a minimum of 1200 shares at an investment of ₹2,49,600 at the upper price band of 208 per share.
Explore Stocks and IPO Research on the Univest Screener
Avience Biomedicals IPO GMP: Should You Apply?
The positive Avience Biomedicals IPO GMP of ₹70 suggests the grey market is currently expecting listing gains, which has historically drawn more retail interest in SME issues. For any SME IPO investment, the GMP is one of many signals. The more important factors are the company’s revenue growth trend, profitability sustainability, peer valuation, promoter background, use of proceeds and the overall SME IPO market environment. SME IPOs carry higher liquidity risk than mainboard issues, and investors should allocate only what they can afford to hold through potential listing-day volatility.
Download the Univest iOS App or Univest Android App to get IPO research and analyst views on Avience Biomedicals and other SME IPOs from Univest.
Conclusion
The Avience Biomedicals IPO GMP on Day 1 of subscription, 18 June 2026, stands at ₹70. The implied expected listing price of ₹278 is approximately 33.7% above the issue price of ₹196 to ₹208, reflecting positive grey market sentiment. The IPO closes on June 22, 2026 and the tentative listing date on NSE SME is June 25, 2026. Investors should track the live subscription data and verify all figures from the official prospectus before making a decision. The Avience Biomedicals IPO GMP will be updated as new grey market data becomes available.
Disclaimer: Data and figures in this article are sourced from publicly available information and live market feeds as of the close of trade on 12 June 2026. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Avience Biomedicals IPO GMP
What is the Avience Biomedicals IPO GMP today on Day 1?
Ans. The Avience Biomedicals IPO GMP on Day 1 of subscription, 18 June 2026, stands at ₹70. This implies an expected listing price of ₹278, approximately 33.7% above the issue price of ₹196 to ₹208.
What is the price band and lot size for the Avience Biomedicals IPO?
Ans. The Avience Biomedicals IPO price band is ₹196 to ₹208 per share with a face value of ₹10. The lot size is 600 shares. Retail investors must apply for a minimum of 1200 shares, requiring an investment of ₹2,49,600 at the upper price band.
When will Avience Biomedicals IPO shares be allotted and listed?
Ans. The Avience Biomedicals IPO allotment is expected on June 23, 2026. Shares will be credited to demat accounts before the listing, which is tentatively scheduled for June 25, 2026 on the NSE SME platform. Refunds for unsuccessful applicants will be processed around the same time.
Is Avience Biomedicals IPO GMP reliable for predicting listing gains?
Ans. The IPO GMP or grey market premium is an unofficial, unregulated indicator and should not be treated as a reliable predictor of listing gains. It reflects sentiment in the informal grey market and can change quickly based on subscription numbers, broader market conditions and demand. Always evaluate the company’s fundamentals, valuation and business model before applying.
What is Avience Biomedicals IPO subscription status on Day 1?
Ans. The Avience Biomedicals IPO opened for subscription on June 18, 2026 and closes on June 22, 2026. Day 1 of the subscription period is 18 June 2026. The final subscription data across retail, QIB and HNI categories will determine allotment probability. Investors should check the live subscription data on NSE or BSE before applying.
What does Avience Biomedicals plan to do with the IPO proceeds?
Ans. According to the offer documents, Avience Biomedicals plans to use the IPO proceeds for working capital requirements, capital expenditure and general corporate purposes. The issue is a book built issue with a total size of ₹30.24 Cr on the NSE SME platform.
Should I apply for the Avience Biomedicals IPO?
Ans. Whether to apply for the Avience Biomedicals IPO depends on your risk appetite, investment horizon and assessment of the company’s fundamentals, valuation and growth prospects. SME IPOs carry higher liquidity risk than mainboard issues. The Avience Biomedicals IPO GMP gives an early sentiment signal, but it is not a recommendation to buy. Consult a SEBI-registered advisor before investing.
